Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2019

View Archived Issues

Enrollment open in phase II trial of ADU-S100 for head and neck cancer

Resistance can be relative, luckily

Better blood supply for better blood sugar control

Acute liver failure can be monogenic condition

3-Substituted quinolines as RORgammat inverse agonists with improved physicochemical properties

Zealand begins phase I trial of ZP-7570 for short bowel syndrome

Bionomics reports results from phase II exploratory study of BNC-210

First patient dosed in phase I/Ib study of PRGN-3006 UltraCART in AML or MDS

Initiation of pivotal phase III clinical trial of mavorixafor for the treatment of WHIM syndrome

Topline data released from phase IIa study of gemcabene in familial partial lipodystrophy

First data presented for novel small-molecule BTK PET tracer

OTG-005: a candidate for the treatment of resistant Gram-negative bacteria

Dupixent obtains U.S. approval for chronic rhinosinusitis with nasal polyposis

European Commission approves Sixmo to treat opioid dependence

Tinostamustine shows efficacy in first-in-human dose-escalation study in lymphoid lymphomas

ENCORE-LF study of emricasan in NASH does not meet primary endpoint

Hanmi Science patents protein kinase inhibitors

NuCana presents new diphosphate phosphoramidate nucleosides for cancer

BIAL-Portela discloses DBH inhibitors

Esteve Pharmaceuticals describes new analgesics

PRMT5 inhibitors described in Angex Pharmaceutical patent

New phase III study explores use of delamanid to prevent people at high risk from developing MDR-TB

Erytech enrolls first patient in TRYbeCA2 trial of eryaspase in first-line TNBC

Verrica reports promising topline data from phase II study of VP-102 in verruca vulgaris

CBD-based antibiotic vanquishes Gram-positive bugs in early test

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...